# Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency

> **NCT03679598** · PHASE2 · COMPLETED · sponsor: **University of Alabama at Birmingham** · enrollment: 63 (actual)

## Conditions studied

- Alpha-1 Antitrypsin Deficiency (AATD)
- Pi*ZZ, Pi*SZ, Pi*Null, Another Rare Phenotype/Genotype Known to be Associated With Either Low or Functionally Impaired AAT Including F or I Mutations
- Emphysema or COPD

## Interventions

- **DRUG:** Alvelestat (MPH966)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03679598
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-08
- **Primary completion:** 2023-11-30
- **Final completion:** 2023-12-01
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2024-08-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03679598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03679598, "Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03679598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*